Learning Objectives
By the end of this session, the learner will be able to explain the Amine Hypothesis of Depression, the mechanism by which Reserpine induces depression, and the clinical paradox between the acute pharmacological effects and the delayed therapeutic onset of antidepressants.
1. The Amine Hypothesis
The Amine Hypothesis suggests that depression is caused by a functional deficiency of monoamine neurotransmitters (Norepinephrine, Serotonin, and Dopamine) in the synaptic cleft of the central nervous system.
| Evidence | Mechanism | Outcome |
|---|---|---|
| Reserpine | Inhibits VMAT (Vesicular Monoamine Transporter). | Depletes NE, 5-HT, and DA; causes severe depression. |
| Antidepressants | Block reuptake or inhibit degradation. | Increases monoamines in the synaptic cleft. |
2. The Clinical Paradox
One of the most important concepts in psychiatric pharmacology is the “Therapeutic Lag.”
Acute Effect: Antidepressants increase neurotransmitter levels within hours of the first dose.
Therapeutic Effect: Improvement in mood and clinical symptoms typically takes 4 to 6 weeks.
| Theory for Delay | Biological Change |
|---|---|
| Receptor Downregulation | Chronic high levels of neurotransmitters cause a decrease in the number of post-synaptic receptors. |
| Neurogenesis | Increased BDNF (Brain-Derived Neurotrophic Factor) leads to the growth of new neurons in the hippocampus. |
3. Classification of Antidepressants
Modern therapy targets various pathways to increase synaptic monoamine concentrations.
| Class | Mechanism | Examples |
|---|---|---|
| SSRIs | Selective Serotonin Reuptake Inhibition. | Fluoxetine, Sertraline. |
| SNRIs | Serotonin and NE Reuptake Inhibition. | Venlafaxine, Duloxetine. |
| TCAs | Non-selective inhibition of NE and 5-HT reuptake. | Amitriptyline, Imipramine. |
| MAOIs | Inhibit breakdown of monoamines. | Phenelzine, Selegiline. |
Clinical Pearls:
- Patient Education: It is vital to tell patients they will not feel “happier” tomorrow. This prevents them from stopping the medication prematurely.
- Suicide Risk: In the first 2 weeks, patients may regain energy (physical activation) before their mood improves, which can temporarily increase the risk of acting on suicidal ideation.
- Reserpine Mechanism: By blocking VMAT, Reserpine prevents neurotransmitters from being packaged into vesicles. They remain in the cytoplasm where they are destroyed by MAO.